Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)

Table 1 Baseline characteristics of patients treated to disease progression, adverse events in the absence of disease progression, and the intent-to-treat population

Patient characteristics	Patients treated to PD		Patients treated to AEs		ITT population[18]
Patient characteristics	nab-P + Gem (n = 224)	Gem (n = 233)	nab-P + Gem (n = 98)	Gem (n = 58)	nab-P + Gem (n = 431)	Gem (n = 430)
Age, median, years	61.0	63.0	66.5	63.5	62.0	63.0
≥ 65 years, %	39	42	55	48	41	44
Male, %, KPS, %	60	58	58	66	57	60
90 %-100 %	60	67	58	57	58	62
70 %-80 %	40	33	41	43	42	38
Current site(s) of metastasis, %
Lung	33	40	38	52	35	43
Liver	90	84	84	79	85	84
No. of metastatic sites, %
1	5	6	7	3	8	5
2	47	50	47	41	47	48
3	32	32	32	31	32	33
>3	15	13	14	24	14	15
Previous Whipple procedure, %	8	7	3	3	7	7
Biliary stent, %	21	15	17	28	19	16

AE adverse event, Gem gemcitabine, ITT intent to treat, KPS Karnofsky performance status, nab-P nab-paclitaxel, PD progressive disease

ISSN: 1471-2407